SE0301371D0 - New Compounds - Google Patents

New Compounds

Info

Publication number
SE0301371D0
SE0301371D0 SE0301371A SE0301371A SE0301371D0 SE 0301371 D0 SE0301371 D0 SE 0301371D0 SE 0301371 A SE0301371 A SE 0301371A SE 0301371 A SE0301371 A SE 0301371A SE 0301371 D0 SE0301371 D0 SE 0301371D0
Authority
SE
Sweden
Prior art keywords
hydrogen
halogen
new compounds
compounds
conr
Prior art date
Application number
SE0301371A
Other languages
Swedish (sv)
Inventor
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301371A priority Critical patent/SE0301371D0/en
Publication of SE0301371D0 publication Critical patent/SE0301371D0/en
Priority to PCT/SE2004/000695 priority patent/WO2004099190A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a compound of Formula I (I) wherein n is 1 or 2; R<1> is selected from hydrogen, halogen, CN, COOR<6,> CONR<6>R<7> or CH2OR<6>; R<2> is selected from hydrogen, halogen or CN; R<3> is selected from hydrogen or halogen; R<4> is selected from hydrogen, COOR<6>, CONR<6> R<7>, NO2, NR<6>R<7>, or NR<6>COR<7>; R<5> selected from hydrogen, NR<6>R<7> or NR<6>COR<7>; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
SE0301371A 2003-05-09 2003-05-09 New Compounds SE0301371D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0301371A SE0301371D0 (en) 2003-05-09 2003-05-09 New Compounds
PCT/SE2004/000695 WO2004099190A1 (en) 2003-05-09 2004-05-06 Novel substituted benzimidazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301371A SE0301371D0 (en) 2003-05-09 2003-05-09 New Compounds

Publications (1)

Publication Number Publication Date
SE0301371D0 true SE0301371D0 (en) 2003-05-09

Family

ID=20291269

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301371A SE0301371D0 (en) 2003-05-09 2003-05-09 New Compounds

Country Status (2)

Country Link
SE (1) SE0301371D0 (en)
WO (1) WO2004099190A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2006078907A1 (en) 2005-01-20 2006-07-27 Amgen Inc. 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments
DK1746097T3 (en) 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridine-fused heterocyclic rings, process for their preparation, use and compositions containing them
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
PT3390367T (en) 2015-12-15 2020-09-23 Univ Leland Stanford Junior Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
CN107141310A (en) * 2016-08-08 2017-09-08 重庆文理学院 A kind of preparation method and applications of novel antibacterial Zn complex
IL307972A (en) 2018-08-06 2023-12-01 Univ Leland Stanford Junior 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63112584A (en) * 1986-10-29 1988-05-17 Yoshitomi Pharmaceut Ind Ltd Imidazopyridine derivative
JPH07121937B2 (en) * 1987-03-18 1995-12-25 大塚製薬株式会社 Carbostyril derivative
US20030008832A1 (en) * 1998-11-25 2003-01-09 Rifat Pamukcu Method of inhibiting neoplastic cells with benzimidazole derivatives
DE19920936A1 (en) * 1999-05-07 2000-11-09 Basf Ag Heterocyclically substituted benzimidazoles, their preparation and use
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Also Published As

Publication number Publication date
WO2004099190A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
IS2376B (en) Thienopyrimidinedione and their use in the development of self-hypersensitivity disease
ATE450533T1 (en) CARBOXAMIDE DERIVATIVES
YU96103A (en) New indole derivatives with 5-ht6 receptor affinity
AR068413A2 (en) 8-AMINO DERIVATIVES, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THERAPY
TNSN03110A1 (en) Azaindoles.
ATE307810T1 (en) IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS
MXPA03011638A (en) 4-piperazinylindole derivatives with 5-ht6 receptor affinity.
NO20070224L (en) 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof
PT1263724E (en) NEW COMPOUNDS
NO20072515L (en) 2-amido-4-phenyltnazole derivatives, preparation and therapeutic use thereof
DE60305724D1 (en) TETRAHYDROCHINOLIN DERIVATIVES THAN CRTH2 ANTAGONISTS
TW200745111A (en) New compounds
MXPA04007414A (en) Substituted indoles as alpha-1 agonists.
NO20075169L (en) New imidazo (1,5-A) ornamental derivatives, process for preparation and pharmaceutical compositions containing the same.
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
TW200606164A (en) New compounds
NO20070837L (en) Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer.
ATE386725T1 (en) HETEROCYCLYL COMPOUNDS
SG171471A1 (en) New benzimidazole derivatives
TW200800984A (en) New compounds
SE0102055D0 (en) New Compounds
SE0102440D0 (en) New compound
SE0301371D0 (en) New Compounds
ATE406363T1 (en) METHYLINDOLES AND METHYLPYRROLOPYRIDINES AS ALPHA-1-ADRENERGIC AGONISTS
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them